---
title: "Guangdong Biolight Meditech Co., Ltd. (300246.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/300246.SZ.md"
symbol: "300246.SZ"
name: "Guangdong Biolight Meditech Co., Ltd."
industry: "Health Care Equipment"
---

# Guangdong Biolight Meditech Co., Ltd. (300246.SZ)

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Location | CN Market |
| Website | [www.blt.com.cn](https://www.blt.com.cn) |

## Company Profile

Guangdong Biolight Meditech Co., Ltd. engages in the research and development, production, sale, and service of medical devices products and solutions in China. It operates in two segments, Life Information and Support, and Kidney Disease. The company offers emergency and critical care monitor, subc...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:09.000Z

**Overall: D (0.61)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 58 / 63 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -0.34% |  |
| Net Profit YoY | 53.78% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 3.06 |  |
| Dividend Ratio | 0.37% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3.50B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 1.05B |  |


**Multi Score**: D

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -5.31% | D |
| Profit Margin | -6.32% | D |
| Gross Margin | 25.12% | C |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -0.34% | D |
| Net Profit YoY | 53.78% | B |
| Total Assets YoY | 1.22% | C |
| Net Assets YoY | -4.81% | D |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -1581.72% | E |
| OCF YoY | -0.34% | D |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.42 | C |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 49.09% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Guangdong Biolight Meditech Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-5.31%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-6.32%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "25.12%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-0.34%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "53.78%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "1.22%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "-4.81%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-1581.72%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-0.34%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.42",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "49.09%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | United Imaging Healthcare (SH.688271) | B | B | C | B | B | B |
| 02 | YUYUE MEDICAL (SZ.002223) | B | B | C | A | C | B |
| 03 | APT (SH.688617) | A | B | B | A | B | B |
| 04 | iRay (SH.688301) | A | B | E | A | B | B |
| 05 | ZHENDE MEDICAL (SH.603301) | C | B | C | B | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -52.92 | 56/66 | - | - | - |
| PB | 3.06 | 32/66 | 2.14 | 1.93 | 1.64 |
| PS (TTM) | 3.35 | 8/66 | 2.40 | 2.15 | 1.87 |
| Dividend Yield | 0.37% | 45/66 | 0.61% | 0.54% | 0.37% |

## Institutional View

### Analyst Rating Distribution

> As of 2024-05-19T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 13.23 |

## References

- [Company Overview](https://longbridge.com/en/quote/300246.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/300246.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/300246.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.